Ultragenyx Pharmaceutical Inc:DTX301组高氨血症危象减少且无死亡病例,优于安慰剂

美股速递
Yesterday

Ultragenyx Pharmaceutical Inc公布的研究数据显示,与安慰剂组相比,其试验性疗法DTX301在治疗期间显著减少了高氨血症危象的发生次数,且该组未出现任何死亡病例。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10